Cynapsus recruits final patient for phase III Parkinson's trial

30 Jun 2016

Dose titration phase results from this study are expected in mid to late July and top-line data in the third quarter.

Parkinson's affects up to 6mln people worldwide

Cynapsus Therapeutics Inc (NASDAQ:CYNA) has completed recruitment for its phase III trial of a film to manage ‘OFF’ period for Parkinson’s disease sufferers.

Dose titration phase results from this study are expected in mid to late July and top-line data in the third quarter.

The drug trial consists of Parkinson’s patients who have at least one OFF episode every 24 hours, with total OFF time of at least two hours per day.

Cynapsus says its drug, APL-130277 is a “turning ON” medication designed to rapidly, safely and reliably convert a PD patient from the OFF to the ON state while avoiding many of the issues associated with subcutaneous delivery of apomorphine.

More than one million people in the US and an estimated 4 to 6 million people worldwide suffer from Parkinson's disease, a chronic progressive neurodegenerative disease that impacts motor activity.

World famous boxer Muhammad Ali was a sufferer, while actor Michael J Fox set up a foundation investigate the disease after he was diagnosed.

http://www.proactiveinvestors.com/companies/news/127726/cynapsus-recruits-final-patient-for-phase-iii-parkinson-s-trial-127726.html